IVVD

Invivyd, Inc. (IVVD) - Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the unaudited quarterly report (Form 10-Q) for Invivyd, Inc. for the period ended March 31, 2026. Invivyd is a biopharmaceutical company focused on monoclonal antibody therapies for viral infectious diseases. Its primary commercial product is PEMGARDA (pemivibart), which received Emergency Use Authorization (EUA) in March 2024 for COVID-19 prevention in immunocompromised individuals. The company is advancing a pipeline including VYD2311 (COVID-19), VBY329 (RSV), and VMS063 (measles).

Key Financial Metrics

Margins: Gross margin on product revenue was approximately 92.5% ($12.7M gross profit / $13.7M revenue). The company does not report a consolidated operating margin due to significant R&D and SG&A expenses exceeding revenue.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by $2.4 million (21.6%) year-over-year, driven by increased demand for PEMGARDA.
• Expense Surge: Total operating expenses increased by $28.7 million to $56.9 million.
  • R&D Expenses: Increased by $20.1 million to $30.7 million. This was primarily due to a $21.3 million increase in costs for the VYD2311 Phase 3 DECLARATION clinical trial.
  • SG&A Expenses: Increased by $8.4 million to $25.1 million, driven by higher professional fees ($5.0M increase) and personnel costs ($2.2M increase).
• Cash Position: Despite a net cash burn of $42.5 million in the quarter, cash balances increased significantly from Q1 2025 due to capital raises in late 2025 (August and November underwritten offerings totaling ~$181.6M net proceeds).
• Lease Obligations: Operating lease liabilities increased significantly due to a new lease for 33,000 sq. ft. of office space in New Haven, CT, commencing March 2026.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Based on current plans and excluding future financing, cash is insufficient to fund operations beyond one year from the filing date.
• Clinical Milestones:
  • VYD2311 (COVID-19): The Phase 3 DECLARATION trial was initiated in December 2025 and upsized in April 2026. Top-line data is expected in Q3 2026. The FDA has granted "Fast Track" designation.
  • VBY329 (RSV) & VMS063 (Measles): Both candidates are in preclinical/IND-enablement stages, with IND readiness targeted for late 2026.
• Capital Needs: The company requires additional funding via equity offerings, debt, or collaborations. It maintains an "At-The-Market" (ATM) facility with $75 million available and a $30 million term loan facility with Silicon Valley Bank (undrawn as of March 31, 2026, due to unmet revenue milestones).
• Risks: Key risks include the uncertainty of clinical trial outcomes, the potential expiration of the public health emergency declaration affecting PEMGARDA's EUA, and the inability to secure additional capital on acceptable terms.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash exhaustion and the company's immediate plan to raise capital given the "substantial doubt" disclosure.
• PEMGARDA Demand: Assess the sustainability of PEMGARDA revenue growth given the reliance on the public health emergency declaration and variant susceptibility.
• VYD2311 Trial Status: Monitor the recruitment progress and data readout timeline for the upsized DECLARATION Phase 3 trial.
• Dilution Risk: Review the terms of the ATM facility and recent equity offerings to understand potential dilution to existing shareholders.
• Debt Covenants: Confirm the specific revenue milestones required to access the $30 million Silicon Valley Bank loan facility.